Table 3 Subgroup analysis of association between RDW and clinical outcome
Variable | No. of trails | HR | 95%CI | P value | Heterogeneity(I2) | |
|---|---|---|---|---|---|---|
Site of infection | ||||||
respiratory tract | 6 | 1.15 | 1.10 | 1.20 | < 0.001 | 71% |
others | 3 | 1.15 | 1.06 | 1.25 | < 0.001 | 50% |
Comorbidity | ||||||
hypertension and DM | 8 | 1.12 | 1.10 | 1.13 | < 0.001 | 81% |
others | 3 | 1.24 | 1.14 | 1.34 | < 0.001 | 70% |
NOS score | ||||||
≥ 7 | 7 | 1.13 | 1.10 | 1.17 | < 0.001 | 14% |
< 7 | 4 | 1.31 | 1.06 | 1.62 | < 0.001 | 87% |
Study design | ||||||
CCS | 6 | 1.08 | 1.06 | 1.10 | < 0.001 | 75% |
RCS | 3 | 1.14 | 1.13 | 1.16 | < 0.001 | 0% |
PCS | 2 | 1.83 | 1.30 | 2.59 | < 0.001 | 10% |
Region | ||||||
Europe or North America | 2 | 1.07 | 1.05 | 1.09 | < 0.001 | 83% |
Asia | 9 | 1.14 | 1.13 | 1.16 | < 0.001 | 53% |